Home 2010 SAN ANTONIO Presentations
2010 Annual Meeting Presentations PDF Print E-mail
Written by jmesina   

Sustaining Care, Seeking a Cure
Grand Hyatt San Antonio, San Antonio Texas
June 2-5, 2010


Please note that the following presentations have been converted to Adobe PDF. Copying of any image is disabled and only low-resolution printing is allowed.


FUNDAMENTALS OF MS CARE

  1. Fundamentals of MS Care: A Case-Based Approach
    Constance B. Easterling, MSN, ARNP, MSCN
    Fundamentals of MS Care A Case-Based Approach offers a multidisciplinary approach to the assessment and management of multiple sclerosis. This program offers a review of MS from diagnosis to case management, including symptom management, psychosocial issues, and adherence. A comprehensive overview of MS will be presented to include epidemiology, immunopathophysiology, diagnostic criteria, pharmacology, and treatments in case-based format. This program will prepare participants for the certification examination.
    Level: Basic

  2. Fundamentals of Rehabilitation
    Patricia Bobryk, MHS, PT, MSCS, PT
    Rehabilitation is an essential component of the comprehensive care model for individuals with MS. This program will provide a brief review of the disease and medical management but focus primarily on issues commonly faced by rehab therapists. Topics include outcome measures, exercise, gait and mobility, fatigue, cognition, speech and swallowing and pharmacology. A multidisciplinary team approach will be emphasized and further illustrated through case studies. This course, in conjunction with ‘Fundamentals of MS Care’, will assist participants in preparing for the MS certification exam.
    Level: Basic and Intermediate

  3. Basic MS Nursing
    Carol Saunders, BSN, MSCN
    This session will include presentations for new nurses without a lot of MS experience about symptom management, supporting patients on their therapy regimes and empowering people with MS to their best quality of life.
    Level: Basic

  4. Advanced Practice Nursing - Nursing Research in Clinical Practice: Making it Happen
    Kathleen Costello, MS, ANP-BC, MSCN
    “I do not have time”. “There are no resources”. “I do not know where to begin”. “I cannot think of anything to research”. These are common statements by nurses and advanced practice nurses when asked about conducting their own research. We all ask research questions every day. Putting them into a format for systematic scientific inquiry is difficult. The advanced practice nursing session will address two important aspects of the research process that can be stumbling blocks to getting research off of the ground. The first half of this session will explore research ideas and study design. We will brainstorm research ideas and discuss how these ideas might be put into an actual trial design. In the second half of the session, we will discuss grants and the grant writing process. In addition, we will discuss where to go and who to ask for funding.
    Level: Intermediate



LECTURES AND WHITAKER TRACK

  1. MS Trivia Bowl
    Allen Bowling, MD, PhD
    The aim for this event is to hopefully provide a little entertainment, but also to educate and provide a forum that can be shared with the diverse professionals at the meeting. It is hoped that it will stimulate interest in subjects or professional areas that may be out of someone’s usual ‘comfort zone.’
    Level: Basic

  2. Meet the Professor Dinner
    Unanticipated Demyelinating Disease of the CNS: Predictors for Disease Progression in Radiologically Isolated Syndrome Subjects
    Darin T. Okuda, MD
    Incidentally identified anomalies within the CNS that are highly suggestive of demyelinating disease have been extensively described in neuropathological series, and are increasingly being detected during premortem investigations. With the exception of studies that focused specifically on the prevalence of this entity, the observed anomalies are unanticipated and unrelated to the intended purpose of the examination. The discovery of MRI technology, and its subsequent widespread adoption in the clinic, has facilitated the identification of such cases. However, the natural course of individuals with incidentally identified demyelinating anomalies is unclear at present. This presentation focuses on the most up-to-date natural history data regarding radiologically isolated syndrome (RIS) subjects, recently identified predictors for disease progression, along with new directions for future investigations.
    Level: Intermediate


  3. Opening Lecture: Emerging Oral Therapies for Multiple Sclerosis
    Jeffrey A. Cohen, MD
    Seven medications are approved by regulatory agencies to treat relapsing multiple sclerosis: interferon-beta (Avonex, Betaseron, Extavia, Rebif), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), and natalizumab (Tysabri). All are effective and generally well-tolerated, but are administered parenterally, which decreases convenience and tolerability. In addition, both mitoxantrone and natalizumab have potential safety issues, so they typically are utilized second-line. A sizable number of medications are being tested as potential new therapies for multiple sclerosis, including several oral agents. Positive phase III studies of two of these oral agents, cladribine and fingolimod (FTY720), recently were reported. Additional oral agents currently in Phase III testing include fumaric acid (BG-12), laquinimod, and teriflunomide. Multiple sclerosis patients and clinicians soon may have a sizable number of new therapeutic options from which to choose. They will need to weigh the anticipated advantages of the new agents vs. the initial relative lack of long-term safety and efficacy data, the already identified safety concerns, the possibility that unanticipated safety issues may arise, and the potential cost of both the medication and potential monitoring.
    Level: Intermediate

  4. Remarkable History of MS Disease Modifying Therapies
    Kenneth Johnson, MD
    From the first clear description of multiple sclerosis (MS) by Charcot in 1868 to the report in 1987 that Cop 1 (glatiramer acetate) significantly improved control of MS, a span of 119 years of therapeutic futility dragged on seemingly without end for both patients and their care givers. In 1993 interferon beta 1b was given FDA approval as the first product marketed for treatment of relapsing MS and within three years a second interferon IFN beta 1a (intramuscular) and glatiramer acetate became commercially available. Soon after a third interferon product, IFN beta 1a (subcutaneous), entered the market and then in 2006 the monoclonal antibody natalizumab gained FDA approval. These pivotal events over the past 20 years have resulted from early historical and medical misconceptions, remarkable persistence, scientific genius and multiple human trials both positive and negative. Hundreds of thousands of MS patients worldwide now benefit as a result of this colorful and unpredictable story.
    Level: Advanced

  5. Whitaker Research Track: What Makes a T Cell Encephalitogenic? Effects of TGF-beta
    Michael Racke, MD
    The Whitaker Track is going to be about cytokines and their relationship to disease in EAE and MS.
    Level: Advanced



CLINICAL COURSES

 

  1. Visual Dysfunction and OCT in Multiple Sclerosis
    Robert Shin, MD
    Visual dysfunction in MS may include vision loss from optic neuritis, diplopia due to brainstem demyelination, and nystagmus from injury to the vestibular/cerebellar balance centers. Visual dysfunction is a common presenting complaint and a source of significant disability and lowered quality of life. This session will help the clinician recognize and manage common types of MS-related visual disorders. The use of optical coherence tomography (OCT) in MS research and clinical practice will also be discussed.
    Level: Basic

  2. Neuroimaging in Multiple Sclerosis
    Corey C. Ford, MD, PhD
    Upon conclusion of this session, participants will be able to:
    • Discuss neuroimaging findings typical of multiple sclerosis
    • Cite MRI changes that support the diagnosis and possible prognosis of MS
    • Identify new imaging techniques in order to facilitate the diagnostic and treatment process in MS
    • Understand how MS affects brain volume
    • Know what non-conventional MRI techniques reveal about the effects of MS on brain metabolism and the molecular structure of axons and supporting cells
    • Relate how the brain performs motor and cognitive tasks in MS and what changes occur to compensate for immune mediated damage
    Level: Basic and Intermediate


  3. Making an Accurate Diagnosis in MS
    Mark Freedman, MSc, MD, FAAN, FRCPC
    Upon conclusion of this session, participants will be able to:
    • Understand the importance of an accurate diagnosis of MS and be familiar with the modalities to assist in doing so
    • Have an approach to review the MRI and distinguish MS from normal variants and disease mimics
    • Be familiar with certain disease mimics and the clinical differential diagnosis of MS
    • Understand the special considerations in making an accurate diagnosis in the pediatric population.
    Level: Basic
  4. Mesenchymal Stem Cell
    Mark Freedman, MSc MD FAAN FRCPC
    Upon conclusion of this presentation, participants will be able to: Differentiate mesenchymal stem cells from embryonic stems cells Discuss the potential benefit of these cells in multiple sclerosis Cite current and emerging research related to the role of mesenchymal stem cells in the clinical course of MS.
    Level: Advanced


  5. Clinical Neuro Anatomy
    Aliza Ben-Zacharia, RN, CRRN, ANP-BC, MSN, MSCN; Stephen Krieger, MD
    The purpose of this program is to demonstrate the correlation between clinical presentations in MS and localization in brain.
    Level: Intermediate


  6. Assessment in Neuro Rehabilitation
    Patricia Bobryk, MHS, PT, MSCS
    Multidisciplinary rehabilitation is an important component in the treatment of MS. A thorough and disease specific assessment is vital in being able to identify barriers to optimal functional independence and in developing an appropriate treatment program. This program will provide information on physical therapy, occupational therapy and speech and language pathology assessments as they pertain to the evaluation of an individual with MS over the course of their disease.
    Level: Basic


  7. Billing and Coding in MS Care
    Anne Dunne, BSN, MBA, MSCN
    The platform for billing and coding in MS care was built upon in/out patient consultation visits, new patient and follow up care visits. Today, comprehensive MS Care centers and private practices specializing in MS care frequently offer an array of in-house ancillary services. These include infusion services, rehabilitative services, evoked potentials, bladder imagery, spasticity management, cognitive therapy and DMT injection services. Patient care is often provided via telephone and other non face to face patient-clinician encounters. This course will review proper coding and billing procedures which capture and optimize reimbursement, and will focus on both physician and non-physician provider services. Case studies will be utilized to demonstrate proper coding and claim follow up procedures.
    Level: Basic




SYMPOSIA

  1. Impact and Management of Acute Attacks
    Dean Wingerchuk, MD
    Clinical attacks are important markers of MS activity that influence diagnosis and treatment, influence natural history of the disease, and impact neurological function and quality of life. This course will describe the impact of attacks on disease course and prognosis, discuss clinical manifestations and therapeutic strategies.
    Level: Intermediate

  2. Update on Therapeutic Monoclonal Antibodies in MS
    Peter A. Calabresi, MD
    A number of monoclonal antibodies (MAb) have been shown to be effective in either phase II or III clinical trials. The course will start with an update on natalizumab providing new information on long-term efficacy data,and additional positive outcomes from the original clinical trials. In addition, an update on PML cases and other potential risks will be provided. The early success of B cell depletion using the anti-CD20 MAbs, rituximab and ocrelizumab will be discussed. Recently, strongly positive phase II data were released for ocrelizumab. Cases of PML have also been seen now in rheumatological diseased patients treated with anti-CD20, but not exposed to anti-TNF therapy, as had been the case previously. Next, progress towards developing the anti-IL-2 receptor alpha MAb, daclizumab, will be reviewed. The details regarding the surprising mechanism of action of this therapy including induction of CD56 bright NK T cells and modulation of antigen presenting cells will be discussed. Finally, an update on anti-CD52 therapy using CAMPath-1, will be provided. This approach has already been shown to be significantly more effective than interferon beta three times weekly, but carried an approximately 25% of autoimmune thyroid disease as well as some risk of the platelet disorder,ITP.
    Level: Intermediate


  3. Risk/Benefit of Emerging Therapies
    Joseph Berger, MD
    Upon conclusion of this presentation, participants will be able to:
    • Recognize the implications of new and emerging therapies in terms of their risk/benefit profile
    • Identify neuro-imaging and other biologic markers for monitoring and safety parameters in multiple sclerosis
    Level: Advanced



  4. The Multiple Roles of the Social Worker in MS: A Look at Case Studies
    Roberta Winter, MSW, LCSW, MSCS
    This symposium will focus on the roles and responsibilities of social workers with ms patients, following case scenarios using audience interaction to develop a best practice standard for the multiple issues faced by the clinical social worker with the ms patient. Ethical dilemmas in ms following the social work code of ethics, involving participation in decision making, self determination, engaging in the helping process, cultural competence and moral distess will inform the discussion.
    Level: Intermediate



  5. Environmental Factors in Multiple Sclerosis
    Christopher Bever, Jr. MD, MBA
    The cause of multiple sclerosis is not known but environmental factors appear to be important contributors to MS risk. This symposium will review the background epidemiology of MS that supports the role of environmental factors in MS risk including viral infection and vitamin D. It will also review new findings suggesting a role for specific viruses, cigarette smoking and sun exposure in MS pathogenesis.
    Level: Intermediate


  6. Mesenchymal Stem Cell
    Mark Freedman, MSc MD FAAN FRCPC
    Upon conclusion of this presentation, participants will be able to: Differentiate mesenchymal stem cells from embryonic stems cells Discuss the potential benefit of these cells in multiple sclerosis Cite current and emerging research related to the role of mesenchymal stem cells in the clinical course of MS. Level: Advanced


  7. How to Work with the CMSC Global Patient Registry
    Timothy Vollmer, MD
    Upon conclusion of this presentation, participants will be able to:

    • Discuss the contribution of the CMSC/NARCOMS patient registry in increasing understanding of the complex issues related to MS
    • Describe the process by which healthcare professionals are able to utilize the database for basic and advanced MS research
    Level: Intermediate

  8. Complex Issues in MS
    Fred Lublin, MD
    This session will be comprised of lectures on Genetics issues - Where next? by P De Jager; Environmental agent- by D Wingerchuk; MRI measures of tissue damage by D Pelletier and Clinical trials for the next generation by J Wolinsky.
    Level: Advanced


  9. Complementary and Alternative Medicine and MS
    Allen Bowling, MD, PhD
    This session will evaluate Complementary and Alternative Medicine (CAM) within the context of multiple sclerosis (MS). The initial lecture will be a brief introduction to CAM and its relevance to MS. The remainder of the lectures will be about specific CAM therapies, including vitamin D, music therapy, hypnosis, and reflexology. These lectures will provide general information about the therapies, summarize MS-specific studies of the therapies, and consider the relevance of the therapies to clinical practice.
    Level: Intermediate


  10. Wheeled Mobility and MS: Walking with Your Hands
    Jodie Haselkorn, MD, MPH
    This panel presentation will address the team approach to managing mobility impairment, the importance of matching patients with the appropriate assistive technology equipment and devices, examine the experience of mobility loss and adaptations, and explore the emerging wheeled mobility options for people with MS.
    Level: Intermediate


  11. Affective and Cognitive Disorders
    Frederick W. Foley, PhD
    The epidemiology of both affective disorders and changes in cognition will be presented. Descriptions of the disorders associated with MS, risk factors, screening and assessment methods, as well as treatment methods will be presented and discussed.
    Level: Intermediate


  12. Defining Suboptimal Response to Therapy
    Patricia Coyle, MD
    This symposium will evaluate current available data on what constitutes a suboptimal response or treatment failure, including unacceptable breakthrough disease activity. A panel discussion will consider suboptimal response using case - based scenarios.  The following topics will be covered:  1. Introduction to the suboptimal responder; the role of compliance / adherence (Dr PK Coyle). 2.   Suboptimal responder: Clinical Criteria (Dr Clyde Markowitz).  3. Suboptimal Responder: Laboratory Criteria (Dr PK Coyle). 4. Suboptimal Responder: Biomarker Criteria  (Dr Bianca Weinstock-Guttmann).  5. Case-Based Panel Discussion (All Speakers).  
    Level: Basic, Intermediate and Advanced


  13. Ethical Principles & Moral Distress: A Case-Based Approach
    Clint Moore, III, MDiv, PhD; Amy Perrin Ross, APN, MSN, CNRN
    Learning Objectives:
    • Describe the history of ethical principles and their use in medical decision-making;
    • Analyze ethical principles in moral decision-making using a case-based approach;
    • Define the concept of moral distress;
    • and
    • Discuss possible solutions and ways to address moral distress in MS patient management.
    Level: Intermediate


  14. Improving Walking in MS: Create your Ambulation Toolbox
    Francois Bethoux, MD, Chair
    This symposium will focus on how to assess and to improve walking performance in patients with MS at various stages of the disease. The speakers will review common gait impairments, and will discuss available interventions (including rehabilitation/exercise, medications, and devices). Published evidence regarding efficacy and safety will be discussed when available. Interactive case presentations will be used to illustrate the decision-making process and outcome assessment. The emphasis is on multidisciplinary management.
    Level: Intermediate

  15. Gender Specific Concerns in MS
    Nancy Sicotte, MD
    Men and women may experience multiple sclerosis differently due to biological, psychological and sociological factors. In this symposium we will explore gender specific concerns regarding MS disease manifestations, disease severity and potential therapeutic interventions. Recognition that gonadal hormones can have profound effects on the immune system has led to insights into disease activity over the reproductive years and to the testing of promising new hormone therapies for both men and women with MS. Topics that will be covered in detail include fertility and reproduction, the effects of hormones and sexuality in people with MS.
    Level: Basic

  16. Wellness and Multiple Sclerosis: Two Perspectives
    Patricia Kennedy, RN, CNP, MSCN
    The words ‘health and wellness’ are frequently used in MS care but carry different meanings depending on the context. Can Do Multiple Sclerosis, formerly The Heuga Center, empowers people to move beyond their MS by giving them the knowledge, skills, tools and confidence to adopt healthy lifestyle behaviors, actively co-manage their disease and live their best lives. During this workshop, we will present two scenarios that approach these topics. From the Care Provider’s perspective, we will present the practicality and impracticality of advocating for a healthy lifestyle for our patients. This includes practical suggestions to incorporate reality in helping patients develop a plan of wellness. From the patient learning perspective, we will present an overview of the design, delivery and results of a blended-learning adaptation of a ‘live’ 12 week comprehensive wellness program.
    Level: Intermediate

  17. Technological Advances in the Assessment and Treatment of Cognitive Difficulties in Persons with Multiple Sclerosis
    John DeLuca, PhD
    This symposium will provide a broad overview of technological advances in the assessment and treatment of cognitive impairment in persons with MS. Dr. David Erlanger will present on the use of computer assessment of cognition in MS, and will also describe recent efforts at “telemedicine” or remote assessment and treatment of cognitive impairment in MS. Dr. John DeLuca will describe the recent use of functional neuroimaging techniques to study cognitive impairment in MS, and will focus specifically on the concept of cognitive reserve and neuroprotection. Dr. Yael Goverover will describe a recent and novel technique called “ Actual Reality”, which uses the internet to assess everyday life activity in persons with MS. Mr. Bob Hone will describe the development and use of the new and rapidly growing area of gaming technology for assessment and treatment of cognition in persons with MS. Lastly, Dr. Albert “Skip” Rizzo will describe the exciting area of Virtual Reality, and how this technology can and is being used in the assessment and treatment of cognition, with particular application to persons with MS.
    Level: Intermediate

  18. LACTRIMS Symposium
    Victor Rivera, MD
    Basic and clinical research being performed in Latin America and preliminary observations of clinical characteristics of Hispanics in the USA constitute the structural themes of this symposium. Presentations on the effect of parasitic infections as well as vitamin D immunology in the course of disease, pregnancy and MS in Venezuelan women, clinical aspects of Hispanic populations with MS in California and CSF analysis report in Latin American will be discussed in this multifacetic symposium.
    Level: Intermediate

WORKSHOPS

  1. Progressive MS
    Patricia Coyle, MD
    This workshop will cover all aspects of progressive MS, including definitions; natural history; clinical features; diagnostic issues; current thinking on etiology, pathology, and pathophysiology; results of therapeutic trials; current treatment strategies ; special symptomatic and psychosocial issues; and future needs.
    Level: Basic, Intermediate and Advanced


  2. The Use of Telephone Triage and Motivational Interviewing Strategies in Complex Patient Dilemmas
    Colleen Harris, MN, NP, MSCN; Patricia Provance, PT, MSCS
    Much of today’s MS patient care is delivered by telephone due to factors such as geography, patient mobility and transportation issues, and the high demand for specialized MS services. Telephone interventions can be challenging and require professionals to operate within their scope of practice and expertise, while performing appropriate health assessments, and delivering education to meet complex care needs. Well thought out interview skills are also necessary to help the patient to modify or change health behaviors. This presentation will focus on the principles of telephone triage for effective coordination of patient care from a distance. It will also review some of the skills of motivational interviewing that can assist patients with the self management of health issues.
    Level: Intermediate


  3. Hospital Admission in Multiple Sclerosis. A Case Study Approach
    Heidi Maloni, PhD, ANP-BC, CNRN, MSCN
    Admission to the hospital for people with multiple sclerosis is mostly a thing of the past. The world of Diagnosis-related groups (DRGs) and cost containment have relegated the diagnosis and management of multiple sclerosis to outpatient settings. The advent of the DRGs created opportunities for outpatient management of disease in clinics, physician offices, infusion centers and in the home. Diagnostic testing is managed in the outpatient setting as well. This session will use an interactive case study approach to exam risk for hospital admission related to multiple sclerosis. Infection, decubitus ulcers, surgical procedures, such as implantation of an intrathecal baclofen pump, gastrostomy, urostomy, tracheostomy and palliative care represent risks for inpatient management of multiple sclerosis symptoms. This session addresses knowledge on an intermediate and advanced level. The panel represents experts in the field of wound care, intrathecal baclofen pump placement and management, as well as, infection management and control.
    Level: Intermediate and Advanced


  4. Basic Immunology in MS
    Ben W. Thrower, MD
    MS is an inflammatory autoimmune disease affecting the CNS. Current and future therapies work primarily by modulating functions of the immune system. A basic understanding of how the human immune system works is crucial for clinicians working with MS. This course is intended for those seeking a basic or perhaps intermediate understanding of basic immunology and how it applies to MS.
    Level: Basic

  5. How to Manage Difficult Patient Situations
    Marie Namey, RN, MSN, MSCN; Ellen Reardon, MSN
    MS is an inflammatory autoimmune disease affecting the CNS. Current and future therapies work primarily by modulating functions of the immune system. A basic understanding of how the human immune system works is crucial for clinicians working with MS. This course is intended for those seeking a basic or perhaps intermediate understanding of basic immunology and how it applies to MS.
    Level: Basic

  6. Plasmapheresis for MS
    Dean Wingerchuk, MD
    This workshop will describe the rationale and evidence supporting the use of plasmapheresis for CNS demyelinating diseases and provide a practical approach to the procedure for neurologists, including equipment, methods, and avoidance and management of potential complications.
    Level: Intermediate


  7. How to Perform an EDSS
    Stephen Kamin, MD
    The EDSS is the most widely used clinical rating scale in multiple sclerosis and is used in most clinical trials. The correct performance of the EDSS is not straightforward and there are ambiguities and pitfalls in its execution. This session will demonstrate the correct performance of the EDSS and discuss difficult issues in scoring the results.
    Level: Intermediate


  8. Infusion Therapy for MS Nurses
    Shirley O’Leary, RN, BSN, MSCN; Cynthia Perry Bishop, BSN, BA
    Outpatient infusion therapy is relatively new, initially beginning in the mid-1970s. Since that time the idea of alternative infusion settings has continued to blossom especially in the field of MS, where the advent of several infusion therapies has propelled us into a new era. The MS nurse is the catalyst for these and future therapies. This workshop will explore the fundamentals of infusion therapy, problem solving, protocols, management strategies and algorithms. Medications, hypersensitivity and infusion reactions will be discussed.
    Level: Intermediate


  9. Sleep Disorders in Multiple Sclerosis
    David Brandes, MS, MD, FAAN; Rock Heyman, MD
    Sleep disorders in the general population are surprisingly common, but some occur with even greater frequency in MS patients. MS patients are not exempt from developing these common sleep disorders independently of their MS. In addition, MS itself can actually cause many sleep disorders. When MS patients report tiredness, sleep disorders must always be considered. Unfortunately, many health care providers have not been trained to identify, evaluate and treat sleep disorders. This course will provide information on sleep disorder diagnosis and treatment, especially in the context of the MS patient.
    Level: Intermediate


  10. Billing and Coding for NPs and PAs
    Anne Dunne, BSN, MBA, MSCN; Jill K. Beavin, RN, BSN, MSCN
    With the many changes in today’s health care delivery system, the team approach can help to streamline efficiency and enhance the quality of patient care delivered. Comprehensive MS Care Centers and private practices specializing in multiple sclerosis are learning that the use of physician assistants and nurse practitioners significantly contribute to improved patient satisfaction while enhancing and broadening the scope of services provided. However, adding an NP or PA requires thoughtful planning, an understanding of the role of these providers, and a thorough knowledge of the billing and coding guidelines appropriate to them. This workshop will discuss the role of NPs and PAs and how they can enhance revenue generation when used appropriately within a practice. Incident to billing guidelines, appropriate level of service coding, and coding/documentation of ancillary services will be presented. The presentation of a time study will be used to demonstrate the added value these providers bring to MS practice settings.
    Level: Basic

    Sample Templates:

  11. Management of Elimination Dysfunction
    Marie Namey, RN, MSN, MSCN
    Bladder and bowel dysfunction are common symptoms in patients with multiple sclerosis (MS). Up to 80% of patients with newly diagnosed MS and up to 96% who have had MS for 10 years or more experience some difficulty with voiding during the course of their illness. Bowel dysfunction has been reported in 65-70% of patients. These symptoms affect quality of life and can be treated successfully when addressed by the clinician. This workshop will explore initial assessments and innovative interventions for bladder management as well as bowel management.
    Level: Intermediate


  12. Pain and its Management in Multiple Sclerosis
    Heidi Maloni, PhD, ANP-BC, CNRN, MSCN; Friedhelm Sandbrink, MD
    Pain as a symptom of multiple sclerosis is difficult to manage. Pain generated by lesions in the central nervous system and pain generated from the mechanics of advanced disease require a biopsychosocial approach to management. This workshop will use an evidenced based, case study approach to the physical and emotional experience of pain in multiple sclerosis and address the pharmaceutical, behavioral, physical and alternative and complimentary modalities to pain management.
    Level: Intermediate and Advanced


  13. Dealing with the Issues of Sexual Dysfunction in MS
    Fred Foley, PhD; Colleen Miller, RN, NP, DNS
    Upon completion of this session, participants will be able to:
    • discuss the physiologic basis of male and female sexual dysfunction
    • describe counseling and educational strategies to address this problem
    • identify professional resources to assist the patient/partner
    • develop a dynamic plan to assess and reassess the issues.
    Level: Intermediate


  14. Meeting the Needs of the Newly Diagnosed with MS
    Rosalind Kalb, PhD; Alan Segaloff, CPA
    Upon completion of this session, participants will be able to:
    • identify resources for newly diagnosed patients and their families provided by members of the MS Coalition
    • describe services that are vital for coping by people who are newly diagnosed with MS
    • examine case studies
    Level: Basic

Last Updated on Monday, 23 August 2010 13:20
 

Search

Banner